Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Can Tiny Synergetics See A Big Surge?

Having made some solid capital gains from various ophthalmology and niche med-tech companies in the past, I looked into Synergetics (NASDAQ:SURG) hoping to find an interesting growth opportunity that the Street has simply not caught on to yet. While I did find a decent company with some growth and capital appreciation potential, the magnitude of that potential was maybe not quite what I was hoping to find. Though I intend to monitor this company in the future to see whether they can capitalize on any disruptions at Valeant's (NYSE:VRX) Bausch + Lomb business, I'm not sure I see quite enough opportunity today to merit a strong recommendation.

Taking On A Giant With Dexterity And Customer...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details